延長(zhǎng)重組人α—2b干擾素抗乙肝病毒治療療程的臨床效果

李火炎

[摘要] 目的 分析研究延長(zhǎng)重組人α-2b干擾素抗乙肝病毒治療療程的臨床效果。 方法 采用單雙號(hào)分組的方式將方便選取的2014年1月—2015年5月期間該院接收的乙肝病毒患者80例分為兩組，分別為對(duì)照組（12個(gè)月治療）和觀察組（18個(gè)月治療），所有患者均接受重組人α-2b干擾素治療，對(duì)兩組患者的肝功能復(fù)常情況、HBeAg轉(zhuǎn)陰情況、HBeAg/HBeAb轉(zhuǎn)換情況以及HBVDNA轉(zhuǎn)陰情況進(jìn)行比較。 結(jié)果 觀察組患者治療結(jié)束時(shí)肝功能復(fù)常占比（95.00%）明顯較對(duì)照組（75.00%）高（χ2=6.27，P<0.05）；于治療結(jié)束時(shí)，觀察組患者的HBeAg轉(zhuǎn)陰占比、HBeAg/HBeAb轉(zhuǎn)換占比比較，差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）；觀察組患者隨訪6個(gè)月、12個(gè)月、18個(gè)月的肝功能復(fù)常占比（95.00%、90.00%、87.50%）、HBVDNA轉(zhuǎn)陰占比（87.50%、45.00%、45.00%）均明顯較對(duì)照組高（P<0.05）；觀察組患者隨訪12個(gè)月及18個(gè)月的HBeAg轉(zhuǎn)陰占比（57.50%、50.00%）、HBeAg/HBeAb轉(zhuǎn)換占比（50.00%、62.50%）亦明顯高于對(duì)照組（P<0.05）。 結(jié)論 延長(zhǎng)重組人α-2b干擾素抗乙肝病毒治療療程可以將疾病復(fù)發(fā)率降低，且有利于提升患者的應(yīng)答率，對(duì)病情進(jìn)展有緩解作用，且有利于降低肝硬化及肝癌的發(fā)生率。

[關(guān)鍵詞] 延長(zhǎng)；重組人α-2b干擾素；乙肝病毒；療程

[中圖分類(lèi)號(hào)] R711 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1674-0742（2019）02（b）-0007-03

Prolonging the Clinical Effect of Recombinant Human α-2b Interferon against Hepatitis B Virus Treatment

LI Huo-yan

Department of Infectious Diseases， Third Hospital of Xiamen， Xiamen， Fujian Province， 361100 China

[Abstract] Objective To analyze the clinical effect of prolonging the treatment of recombinant human α-2b interferon against hepatitis B virus. Methods 80 patients （hepatitis B from January 2014 to May 2015） received by the hospital were divided into two groups， the control group （12 months treatment） and the observation group （18 months treatment）. All patients were treated with recombinant human α-2b interferon， and the liver function， HBeAg negative， HBeAg/HBeAb transition， and HBVDNA negative were compared between the two groups. Results In the observation group， the proportion of liver function recurrence （95.00%） was significantly higher than that of the control group （75.00%） （χ2=6.27， P<0.05）. At the end of treatment， the HBeAg ratio， HBeAg/HBeAb conversion ratio of the observation group was not significantly different（P>0.05）； patients in the observation group were followed up for 6 months， 12 months， 18 months， and the proportion of liver function recurrence （95.00%， 90.00%， 87.50%）， HBVDNA proportion of negative conversion （87.50%， 45.00%， 45.00%） was significantly higher than that of the control group（P<0.05）. The patients in the observation group were followed up for 12 months and 18 months for HBeAg transfer ratio of yin （57.50%， 50.00%） and HBeAg/HBeAb conversion （50.00%， 62.50%） was also significantly higher than that of the control group（P<0.05）. Conclusion Prolonging the treatment of recombinant human α-2b interferon against hepatitis B virus can reduce the recurrence rate of the disease， and it is beneficial to improve the response rate of patients， and it can alleviate the progress of the disease， and it is beneficial to reduce the incidence of liver cirrhosis and liver cancer.